Vigil Neuroscience is a microglia-focused company dedicated to improving the lives of patients, caregivers and families affected by rare and common neurodegenerative diseases. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system health and responding to damage caused by disease. Leveraging recent research implicating microglial dysfunction in neurodegenerative diseases, we utilize a precision medicine approach to develop a pipeline of therapeutic candidates, initially addressing genetically defined patient subpopulations, that we believe will activate and restore microglial function. We are initially developing our lead candidate, VGL101, for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare, genetically defined, and fatal neurodegenerative disease. In November 2021, the FDA cleared our Investigational New Drug application for VGL101. We plan to begin our first-in-human Phase 1 clinical trial in December 2021. We are also developing a novel small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. The initial focus is for the treatment of Alzheimer’s disease in genetically defined patient subpopulations. We expect to select a development candidate by the first quarter of 2022.